Literature DB >> 16847443

Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion.

Emanuela Masini1, Salvatore Cuzzocrea, Emanuela Mazzon, Carmelo Muià, Alfredo Vannacci, Francesca Fabrizi, Daniele Bani.   

Abstract

1. Splanchnic artery occlusion (SAO) followed by reperfusion causes endothelial injury and inflammation which contribute to the pathophysiology of shock. We investigated the effects of relaxin (RLX), known to afford protection against the deleterious effects of cardiac ischemia/reperfusion, given to rats subjected to splanchnic artery occlusion and reperfusion (SAO/R)-induced splanchnic injury. 2. RLX (30 ng kg(-1), 15 min. before reperfusion) significantly reduced the drop of blood pressure and high mortality rate caused by SAO/R. RLX also reduced histopathological changes, leukocyte infiltration (myeloperoxidase) and expression of endothelial cell adhesion molecules in the ileum. RLX counteracted free radical-mediated tissue injury, as judged by significant decrease in the tissue levels of peroxidation and nitration products (malondialdehyde, nitrotyrosine), DNA damage markers (8-hydroxy-2'-deoxyguanosine, poly-ADP-ribosylated DNA) and consumption of tissue antioxidant enzymes (superoxide dismutase). As a result, RLX led to a reduction of ileal cell apoptosis (caspase 3, terminal deoxynucleotidyltransferase-mediated UTP end labeling). The effects of RLX appear specific, as inactivated RLX substituted for the bioactive hormone had no effects. 3. In conclusion, these results show that RLX exerts a clear-cut protective effect in SAO/R-induced splanchnic injury, likely due to endothelial protection, decreased leukocyte recruitment and hindrance of free radical-mediated tissue injury leading to cell death, lethal complications and high mortality rate. Thus, RLX could be used therapeutically in intestinal ischemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847443      PMCID: PMC1752008          DOI: 10.1038/sj.bjp.0706811

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  68 in total

Review 1.  Relaxin in vascular physiology and pathophysiology: possible implications in ischemic brain disease.

Authors:  Silvia Nistri; Daniele Bani
Journal:  Curr Neurovasc Res       Date:  2005-07       Impact factor: 1.990

2.  Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion.

Authors:  S Cuzzocrea; E Mazzon; L Dugo; A P Caputi; K Aston; D P Riley; D Salvemini
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model.

Authors:  Avio-Maria Perna; Emanuela Masini; Silvia Nistri; Vittorio Briganti; Laura Chiappini; Pierluigi Stefano; Mario Bigazzi; Cesco Pieroni; Tatiana Bani Sacchi; Daniele Bani
Journal:  FASEB J       Date:  2005-07-11       Impact factor: 5.191

4.  Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells.

Authors:  Paola Failli; Silvia Nistri; Silvia Quattrone; Luca Mazzetti; Mario Bigazzi; Tatiana Bani Sacchi; Daniele Bani
Journal:  FASEB J       Date:  2001-12-14       Impact factor: 5.191

5.  Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite.

Authors:  C Szabó; S Cuzzocrea; B Zingarelli; M O'Connor; A L Salzman
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

Review 6.  Role of nitric oxide in the regulation of acute and chronic inflammation.

Authors:  F S Laroux; D J Lefer; S Kawachi; R Scalia; A S Cockrell; L Gray; H Van der Heyde; J M Hoffman; M B Grisham
Journal:  Antioxid Redox Signal       Date:  2000       Impact factor: 8.401

Review 7.  Diagnosis and management of ischemic colitis.

Authors:  Jayaprakash Sreenarasimhaiah
Journal:  Curr Gastroenterol Rep       Date:  2005-10

Review 8.  Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion.

Authors:  C Szabó; V L Dawson
Journal:  Trends Pharmacol Sci       Date:  1998-07       Impact factor: 14.819

9.  Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion.

Authors:  S Cuzzocrea; B Zingarelli; G Costantino; A Szabó; A L Salzman; A P Caputi; C Szabó
Journal:  Br J Pharmacol       Date:  1997-07       Impact factor: 8.739

10.  Change of Cu,Zn-superoxide dismutase activity of guinea pig lung in experimental asthma.

Authors:  Shozo Nishida; Kazuhiro Teramoto; Saori Kimoto-Kinoshita; Yuji Tohda; Shigenori Nakajima; Takanori T Tomura; Kiyohiro Irimajiri
Journal:  Free Radic Res       Date:  2002-06
View more
  18 in total

1.  Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction.

Authors:  Jesus Sanchez-Mas; Antonio Lax; Mari C Asensio-Lopez; Miriam Lencina; Maria J Fernandez-Del Palacio; Angela Soriano-Filiu; Rudolf A de Boer; Domingo A Pascual-Figal
Journal:  J Cardiovasc Transl Res       Date:  2017-07-17       Impact factor: 4.132

Review 2.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 3.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

4.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

5.  Olprinone attenuates the development of ischemia/reperfusion injury of the gut.

Authors:  Concetta Crisafulli; Emanuela Mazzon; Maria Galuppo; Irene Paterniti; Rocco Caminiti; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2010-03-27       Impact factor: 17.440

6.  Relaxin peptide hormones are protective during the early stages of ischemic stroke in male rats.

Authors:  Lindsay H Bergeron; Jordan M Willcox; Faisal J Alibhai; Barry J Connell; Tarek M Saleh; Brian C Wilson; Alastair J S Summerlee
Journal:  Endocrinology       Date:  2014-12-02       Impact factor: 4.736

7.  Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.

Authors:  Jennifer M Sasser; Mark W Cunningham; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2014-10-08

8.  Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

9.  Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for allergic airways disease.

Authors:  K P Patel; A S Giraud; C S Samuel; S G Royce
Journal:  Br J Pharmacol       Date:  2016-05-05       Impact factor: 8.739

10.  Proteolytic Activity Attenuates the Response of Endothelial Cells to Fluid Shear Stress.

Authors:  Angelina E Altshuler; Mary J Morgan; Shu Chien; Geert W Schmid-Schönbein
Journal:  Cell Mol Bioeng       Date:  2012-03       Impact factor: 2.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.